In AML, patients with high STING expression harbored more FLT3 and DNMT3A mutations (P = 0.038 and P = 0.047, respectively) but fewer RUNX1 and TP53 mutations (P = 0.048 and P = 0.018, respectively) than those with low STING expression (Supplementary Figure S1). This evidence concerns the gene TP53 and acute myeloid leukemia.